Marshall Wace North America L.P. lifted its holdings in shares of MyoKardia, Inc. (NASDAQ:MYOK) by 28.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,274 shares of the biotechnology company’s stock after purchasing an additional 33,970 shares during the period. Marshall Wace North America L.P. owned about 0.49% of MyoKardia worth $2,019,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fernwood Investment Management LLC raised its stake in shares of MyoKardia by 0.8% during the 1st quarter. Fernwood Investment Management LLC now owns 43,323 shares of the biotechnology company’s stock worth $570,000 after purchasing an additional 327 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of MyoKardia by 5.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,680 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 2,394 shares during the period. Rhumbline Advisers raised its stake in shares of MyoKardia by 45.4% during the 2nd quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 5,773 shares during the period. Bank of New York Mellon Corp raised its stake in shares of MyoKardia by 11.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 63,208 shares of the biotechnology company’s stock worth $828,000 after purchasing an additional 6,603 shares during the period. Finally, Teachers Advisors LLC raised its stake in shares of MyoKardia by 42.1% during the 4th quarter. Teachers Advisors LLC now owns 28,145 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 8,342 shares during the period. Institutional investors own 48.38% of the company’s stock.

MYOK has been the topic of a number of recent analyst reports. BMO Capital Markets reiterated a “buy” rating and set a $45.00 target price (up from $32.00) on shares of MyoKardia in a research note on Tuesday, August 8th. TheStreet upgraded MyoKardia from a “d+” rating to a “c” rating in a research note on Thursday, July 6th. ValuEngine upgraded MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Cowen and Company lifted their target price on MyoKardia from $28.00 to $56.00 and gave the stock an “outperform” rating in a research note on Monday, August 7th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $48.00 target price (up from $31.00) on shares of MyoKardia in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $41.60.

Shares of MyoKardia, Inc. (MYOK) opened at 43.75 on Tuesday. The stock’s market cap is $1.38 billion. MyoKardia, Inc. has a one year low of $10.55 and a one year high of $46.80. The company has a 50-day moving average price of $29.56 and a 200 day moving average price of $17.40.

MyoKardia (NASDAQ:MYOK) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.04. MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The firm had revenue of $5.60 million during the quarter, compared to the consensus estimate of $6.73 million. During the same period in the prior year, the company posted ($0.37) EPS. The firm’s revenue was up 60.0% compared to the same quarter last year. Equities research analysts expect that MyoKardia, Inc. will post ($1.64) earnings per share for the current year.

In other MyoKardia news, insider Joseph Lambing sold 5,000 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $45.00, for a total value of $225,000.00. Following the transaction, the insider now owns 99,718 shares of the company’s stock, valued at $4,487,310. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Sanofi bought 350,000 shares of the stock in a transaction on Monday, August 14th. The stock was purchased at an average cost of $35.50 per share, for a total transaction of $12,425,000.00. The disclosure for this purchase can be found here. In the last three months, insiders sold 77,288 shares of company stock worth $1,866,236. 46.10% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/05/myokardia-inc-myok-stake-raised-by-marshall-wace-north-america-l-p.html.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Stock Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related stocks with our FREE daily email newsletter.